Pfizer Gets PTAB To Review Neulasta Patent In Amgen IP Row
The Patent Trial and Appeal Board has agreed to review an Amgen patent covering its blockbuster anti-infection drug Neulasta in a challenge brought by Pfizer and Hospira, rejecting Amgen's argument that...To view the full article, register now.
Already a subscriber? Click here to view full article